Cargando…

Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel disease

BACKGROUND: Inflammatory bowel disease constitutes a heterogeneous group of conditions, whose aetiology is only partly understood. The prevailing hypothesis on its pathogenesis is that IBD is the result of an inadequate immune response to the resident bacterial flora of the intestine. An autoimmune...

Descripción completa

Detalles Bibliográficos
Autores principales: Frede, Natalie, Glocker, Erik-Oliver, Wanders, Jennifer, Engelhardt, Karin R, Kreisel, Wolfgang, Ruemmele, Frank M, Grimbacher, Bodo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942769/
https://www.ncbi.nlm.nih.gov/pubmed/24581234
http://dx.doi.org/10.1186/1471-2172-15-10
_version_ 1782479123821625344
author Frede, Natalie
Glocker, Erik-Oliver
Wanders, Jennifer
Engelhardt, Karin R
Kreisel, Wolfgang
Ruemmele, Frank M
Grimbacher, Bodo
author_facet Frede, Natalie
Glocker, Erik-Oliver
Wanders, Jennifer
Engelhardt, Karin R
Kreisel, Wolfgang
Ruemmele, Frank M
Grimbacher, Bodo
author_sort Frede, Natalie
collection PubMed
description BACKGROUND: Inflammatory bowel disease constitutes a heterogeneous group of conditions, whose aetiology is only partly understood. The prevailing hypothesis on its pathogenesis is that IBD is the result of an inadequate immune response to the resident bacterial flora of the intestine. An autoimmune background, however, has been discussed since the 1950s. Lately, it has been shown that failures in interleukin-10 (IL-10) signalling due to IL-10- and IL-10 receptor (IL-10R) mutations result in IBD. Our study aimed at investigating the existence of inhibitory autoantibodies against IL-10 and IL-10R in IBD patients capable of down-modulating IL-10 signalling thereby mimicking IL-10 or IL-10R deficiency. RESULTS: Thirteen IBD patients had IgG autoantibodies against IL-10, IL-10RA and/or IL-10RB, and three patients had IgA autoantibodies against IL-10. However, the absolute OD values of the serum antibodies measured by ELISA were low, there was overall no significant difference between patients and controls, and positive sera had no neutralizing activity. CONCLUSION: No evidence for an involvement of autoantibodies against IL-10 or IL-10R in the pathogenesis of inflammatory bowel disease could be established.
format Online
Article
Text
id pubmed-3942769
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39427692014-03-06 Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel disease Frede, Natalie Glocker, Erik-Oliver Wanders, Jennifer Engelhardt, Karin R Kreisel, Wolfgang Ruemmele, Frank M Grimbacher, Bodo BMC Immunol Research Article BACKGROUND: Inflammatory bowel disease constitutes a heterogeneous group of conditions, whose aetiology is only partly understood. The prevailing hypothesis on its pathogenesis is that IBD is the result of an inadequate immune response to the resident bacterial flora of the intestine. An autoimmune background, however, has been discussed since the 1950s. Lately, it has been shown that failures in interleukin-10 (IL-10) signalling due to IL-10- and IL-10 receptor (IL-10R) mutations result in IBD. Our study aimed at investigating the existence of inhibitory autoantibodies against IL-10 and IL-10R in IBD patients capable of down-modulating IL-10 signalling thereby mimicking IL-10 or IL-10R deficiency. RESULTS: Thirteen IBD patients had IgG autoantibodies against IL-10, IL-10RA and/or IL-10RB, and three patients had IgA autoantibodies against IL-10. However, the absolute OD values of the serum antibodies measured by ELISA were low, there was overall no significant difference between patients and controls, and positive sera had no neutralizing activity. CONCLUSION: No evidence for an involvement of autoantibodies against IL-10 or IL-10R in the pathogenesis of inflammatory bowel disease could be established. BioMed Central 2014-02-28 /pmc/articles/PMC3942769/ /pubmed/24581234 http://dx.doi.org/10.1186/1471-2172-15-10 Text en Copyright © 2014 Frede et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Research Article
Frede, Natalie
Glocker, Erik-Oliver
Wanders, Jennifer
Engelhardt, Karin R
Kreisel, Wolfgang
Ruemmele, Frank M
Grimbacher, Bodo
Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel disease
title Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel disease
title_full Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel disease
title_fullStr Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel disease
title_full_unstemmed Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel disease
title_short Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel disease
title_sort evidence for non-neutralizing autoantibodies against il-10 signalling components in patients with inflammatory bowel disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942769/
https://www.ncbi.nlm.nih.gov/pubmed/24581234
http://dx.doi.org/10.1186/1471-2172-15-10
work_keys_str_mv AT fredenatalie evidencefornonneutralizingautoantibodiesagainstil10signallingcomponentsinpatientswithinflammatoryboweldisease
AT glockererikoliver evidencefornonneutralizingautoantibodiesagainstil10signallingcomponentsinpatientswithinflammatoryboweldisease
AT wandersjennifer evidencefornonneutralizingautoantibodiesagainstil10signallingcomponentsinpatientswithinflammatoryboweldisease
AT engelhardtkarinr evidencefornonneutralizingautoantibodiesagainstil10signallingcomponentsinpatientswithinflammatoryboweldisease
AT kreiselwolfgang evidencefornonneutralizingautoantibodiesagainstil10signallingcomponentsinpatientswithinflammatoryboweldisease
AT ruemmelefrankm evidencefornonneutralizingautoantibodiesagainstil10signallingcomponentsinpatientswithinflammatoryboweldisease
AT grimbacherbodo evidencefornonneutralizingautoantibodiesagainstil10signallingcomponentsinpatientswithinflammatoryboweldisease